Wegovy UK: Complete Patient Guide

Wegovy is the brand name for semaglutide at a dose of 2.4mg, manufactured by Novo Nordisk specifically for weight management. It is the same active molecule as Ozempic (semaglutide 0.25–1mg for type 2 diabetes) but at a higher dose optimised for appetite suppression and weight loss.

Mechanism of action — GLP-1 receptor agonism:

Semaglutide mimics a natural hormone called GLP-1 (glucagon-like peptide-1) that your body releases after eating. By activating GLP-1 receptors, Wegovy produces several effects:

• •Appetite suppression: Acts on GLP-1 receptors in the hypothalamus to reduce hunger and increase feelings of fullness (satiety)
• •Slowed gastric emptying: Food moves through the stomach more slowly, prolonging the feeling of being full after meals
• •Enhanced insulin secretion: Stimulates insulin release in response to food (glucose-dependent), improving blood sugar regulation
• •Reduced glucagon release: Suppresses the hormone glucagon, which normally signals the liver to release glucose into the bloodstream
• •Potential central nervous system effects: Emerging research suggests GLP-1 agonists may influence food reward pathways in the brain, reducing cravings and the psychological drive to eat

Administration:

Wegovy is administered as a once-weekly subcutaneous injection using a pre-filled FlexTouch pen. The injection is typically given in the abdomen, thigh, or upper arm, and can be self-administered at home after an initial training session. The injection day should remain consistent each week, though the exact time of day does not need to be the same.

Key distinction from Ozempic:

While Wegovy and Ozempic contain the same active ingredient (semaglutide), they are licensed for different indications. Ozempic is licensed for type 2 diabetes at lower doses (0.25–1mg, with a 2mg option). Wegovy is specifically licensed for chronic weight management at the 2.4mg dose. Using Ozempic "off-label" for weight loss, while common, means using a diabetes medication outside its licensed indication.

Wegovy is available on the NHS for weight management, but access is subject to specific eligibility criteria set out in NICE guidance. Understanding these criteria helps you determine whether you may qualify.

NICE-recommended eligibility criteria:

Wegovy may be prescribed on the NHS for adults who meet all of the following:

• •BMI of 30 or above (classified as obese), or BMI of 27 or above with at least one weight-related comorbidity such as:
• • - Type 2 diabetes or pre-diabetes
• • - Hypertension (high blood pressure)
• • - Obstructive sleep apnoea
• • - Cardiovascular disease
• • - Non-alcoholic fatty liver disease
• • - Osteoarthritis in weight-bearing joints

• •Have been referred to or are being managed by a specialist weight management service (Tier 3 or equivalent)

• •BMI thresholds may be adjusted downward by 2.5 points for people of South Asian, Chinese, or other ethnic backgrounds where metabolic risk occurs at lower BMI values

The NHS pathway:

1. GP referral: Your GP assesses whether you meet the initial criteria and refers you to a specialist weight management service 2. Tier 3 specialist service: A multidisciplinary team (typically including a dietitian, psychologist, physician, and exercise specialist) conducts a comprehensive assessment 3. Lifestyle intervention: You will usually be expected to engage with dietary, behavioural, and physical activity interventions as part of the programme 4. Pharmacotherapy decision: The specialist team decides whether to offer pharmacotherapy (including Wegovy) as part of the overall weight management plan 5. Monitoring and review: Regular follow-up appointments to monitor progress, side effects, and clinical response. NICE recommends review at 6 months — if less than 5% weight loss has been achieved, treatment should be reconsidered

Practical realities of NHS access:

• •Waiting lists: Tier 3 weight management services in many areas of the UK have significant waiting lists, sometimes exceeding 12 months
• •Postcode lottery: Availability of Wegovy specifically (versus other weight management medications) varies by local NHS trust and commissioning decisions
• •Supply constraints: Wegovy has experienced intermittent supply issues in the UK since its launch. Your pharmacy may need to order it specifically
• •Treatment duration: NICE guidance recommends a maximum treatment duration of 2 years, with reassessment thereafter

The evidence base for Wegovy comes from the STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial programme — one of the most comprehensive anti-obesity medication trial programmes ever conducted.

STEP 1 (2021) — The landmark trial:

• •1,961 adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one comorbidity
• •Participants did not have type 2 diabetes
• •68-week treatment duration
• •Results:
• • - Semaglutide 2.4mg: 14.9% mean weight loss (approximately 15.3kg)
• • - Placebo: 2.4% mean weight loss
• • - Over one-third of participants lost more than 20% of their body weight
• • - Significant improvements in waist circumference, blood pressure, blood lipids, and inflammatory markers

STEP 2 (2021) — Diabetes population:

• •1,210 adults with type 2 diabetes and overweight/obesity
• •68-week treatment duration
• •Results: 9.6% mean weight loss with semaglutide 2.4mg (compared to 3.4% placebo) — less than in non-diabetic patients, which is consistent with the observation that diabetes makes weight loss more challenging

STEP 3 (2021) — With intensive behavioural therapy:

• •Combined semaglutide 2.4mg with intensive lifestyle intervention (meal replacements, increased physical activity, frequent counselling)
• •Results: 16.0% mean weight loss — demonstrating that combining medication with intensive lifestyle support produces the best outcomes

STEP 4 (2021) — Withdrawal study:

• •Patients who discontinued semaglutide after 20 weeks of treatment regained approximately two-thirds of their lost weight over the subsequent 48 weeks
• •This study underscored that semaglutide-mediated weight loss requires ongoing treatment for maintenance — obesity is a chronic condition requiring chronic treatment

STEP 5 (2022) — Long-term data:

• •2-year treatment data showing sustained weight loss of approximately 15% at 104 weeks
• •Demonstrated durability of effect with continued treatment

SELECT trial (2023) — Cardiovascular outcomes:

Perhaps the most significant finding for semaglutide came from the SELECT trial:

• •17,604 adults with established cardiovascular disease and overweight/obesity (without diabetes)
• •Semaglutide 2.4mg reduced major adverse cardiovascular events (MACE) — heart attack, stroke, and cardiovascular death — by 20% compared to placebo
• •This was the first time any anti-obesity medication demonstrated a direct cardiovascular mortality benefit
• •The SELECT data significantly strengthened the case for treating obesity as a cardiovascular risk factor, not merely a cosmetic concern

Wegovy uses a 5-step dose escalation protocol over 16 weeks, designed to build tolerance gradually and minimise gastrointestinal side effects.

The standard dose escalation schedule:

| Dose | Duration | Pen colour | Purpose | |------|----------|------------|---------| | 0.25mg | Weeks 1–4 | Dark blue | Initiation dose — building tolerance | | 0.5mg | Weeks 5–8 | Purple/violet | Continued tolerability building | | 1mg | Weeks 9–12 | Light blue | Therapeutic effects begin | | 1.7mg | Weeks 13–16 | Orange/brown | Approaching full therapeutic dose | | 2.4mg | Week 17 onwards | Dark red | Full maintenance dose |

What to expect at each stage:

• •Weeks 1–4 (0.25mg): Minimal appetite changes for most patients. This dose is sub-therapeutic — its purpose is solely to allow your GI system to adjust. Weight loss of 0–1kg is typical
• •Weeks 5–8 (0.5mg): Some patients begin to notice mild appetite suppression. Nausea may appear for the first time at this dose
• •Weeks 9–12 (1mg): Noticeable appetite suppression for most patients. This is the first truly therapeutic dose. Portion sizes typically decrease naturally. Nausea may increase temporarily
• •Weeks 13–16 (1.7mg): Significant appetite suppression. Weight loss accelerates. GI side effects may resurge briefly at this dose before settling
• •Week 17+ (2.4mg): Full maintenance dose. Maximum appetite suppression. Most patients report that their relationship with food has fundamentally changed — eating is driven by necessity rather than desire

Practical guidance:

• •Missed dose: If you miss a dose and it has been less than 5 days since the scheduled dose, take it as soon as possible. If more than 5 days have passed, skip the missed dose and take the next one on schedule. Do not double up
• •Injection rotation: Rotate injection sites between the abdomen, thigh, and upper arm to reduce the risk of injection site reactions and lipodystrophy
• •Storage: Unused pens should be stored in a refrigerator (2–8°C). A pen in use can be kept at room temperature (below 30°C) for up to 28 days
• •Timing: Choose a consistent day of the week for your injection. Many patients prefer Friday or Saturday in case of initial GI side effects during dose escalation

If side effects are problematic:

Your prescriber may recommend staying at a particular dose for longer than 4 weeks before escalating, or may decide that a lower maintenance dose (e.g., 1.7mg rather than 2.4mg) provides adequate benefit with better tolerability. The dose escalation schedule is a guideline, not a rigid requirement.

Wegovy's side effect profile is well-characterised from the extensive STEP trial programme. The majority of side effects are gastrointestinal, dose-related, and tend to diminish over time.

Very common (more than 1 in 10 patients):

• •Nausea: The most frequently reported side effect, affecting approximately 40–45% of patients at some point during treatment. Most common during dose escalation and typically improves within 2–4 weeks at each dose level
• •Diarrhoea: Affects approximately 25–30% of patients. Usually mild to moderate
• •Constipation: Affects approximately 20–25% of patients. Can be managed with fibre and hydration
• •Vomiting: Affects approximately 20–25% of patients, more common during dose escalation

Common (1–10% of patients):

• •Abdominal pain: Usually mild and intermittent
• •Headache: Particularly in the early weeks of treatment
• •Fatigue: Some patients report reduced energy, especially during the initiation phase when caloric intake drops significantly
• •Dyspepsia: Indigestion, bloating, and acid reflux
• •Dizziness: Occasionally reported, may be related to reduced food intake
• •Injection site reactions: Mild redness, swelling, or itching — usually temporary

Uncommon but clinically significant:

• •Gallbladder disease: Rapid weight loss increases gallstone risk. Watch for severe upper abdominal pain, particularly after fatty meals. The risk is proportional to the rate and magnitude of weight loss
• •Pancreatitis: Rare but serious. Persistent severe abdominal pain radiating to the back requires immediate medical attention
• •Acute kidney injury: Very rare, but can occur secondary to dehydration from severe vomiting or diarrhoea. Maintain adequate hydration

Effective management strategies:

• •For nausea: Eat smaller meals more frequently (5–6 small meals rather than 3 large ones). Avoid fatty, fried, or heavily spiced foods. Ginger tea or ginger supplements can help. Eating bland foods (toast, rice, bananas) during acute nausea episodes
• •For constipation: Increase fibre intake gradually (aim for 25–30g/day). Drink at least 2 litres of water daily. Consider psyllium husk or a gentle osmotic laxative if dietary measures are insufficient
• •For diarrhoea: Stay hydrated. Avoid artificial sweeteners (sorbitol, maltitol) which can worsen symptoms. If persistent, discuss with your prescriber
• •For fatigue: Ensure adequate protein intake (1.2–1.6g/kg body weight). Severe caloric restriction beyond what the medication naturally produces is counterproductive

When to contact your prescriber urgently:

• •Severe, persistent abdominal pain (especially radiating to the back)
• •Inability to keep fluids down for more than 24 hours
• •Signs of severe dehydration (very dark urine, confusion, rapid heartbeat)
• •Signs of allergic reaction (facial swelling, difficulty breathing, widespread rash)
• •Symptoms of hypoglycaemia if you are also taking diabetes medications (shakiness, sweating, confusion)

Wegovy availability in the UK has been subject to fluctuations since its launch. Understanding the supply situation helps you plan ahead and avoid treatment interruptions.

Current supply status (early 2026):

Novo Nordisk has significantly expanded manufacturing capacity since the initial supply constraints of 2023–2024. Availability has improved, though intermittent shortages of specific dose strengths still occur. The 0.25mg and 0.5mg initiation doses tend to have the most stable supply, while the 1.7mg and 2.4mg maintenance doses occasionally experience stock pressure due to the growing number of patients reaching maintenance.

Where Wegovy is dispensed:

• •Community pharmacies: Major chains and independent pharmacies can order Wegovy, though not all keep it in stock routinely. It is advisable to call ahead
• •Online pharmacies: Several GPhC-registered online pharmacies supply Wegovy, often with next-day delivery. Verify GPhC registration at pharmacyregulation.org
• •Hospital pharmacies: For patients accessing Wegovy through NHS specialist services
• •Private clinic dispensing: Some private clinics dispense Wegovy directly through their in-house pharmacy (which must be GPhC registered)

Tips for managing supply:

• •Order your next pen at least 1–2 weeks before your current one runs out
• •Ask your pharmacy to set up a regular monthly order
• •If your usual pharmacy cannot source a particular dose, ask your prescriber about temporary dose adjustments (e.g., using two lower-dose pens to approximate the target dose)
• •Register with a backup pharmacy that stocks Wegovy

Cost through private channels:

Private prescription costs for Wegovy typically range from £200–£300 per month at the maintenance dose. Costs vary between pharmacies, so it is worth comparing:

• •Some online pharmacies offer subscription pricing with a modest discount
• •The cost per pen is generally higher for the maintenance doses (1.7mg and 2.4mg) than for the initiation doses
• •Consultation fees (£100–£250 initial, £75–£150 follow-up) are additional

SELECT cardiovascular data and its impact on access:

The SELECT trial's cardiovascular outcome data has strengthened the clinical and economic case for semaglutide in patients with cardiovascular risk. This data may influence future NICE guidance to broaden NHS eligibility criteria, though any such change would take time to implement through the commissioning process.

Successfully using Wegovy involves more than just the weekly injection. Here is practical guidance for getting the best outcomes and planning for the long term.

Maximising effectiveness:

• •Dietary quality matters: While Wegovy reduces appetite, the nutritional quality of what you do eat becomes more important when consuming less food overall. Prioritise protein (to preserve muscle mass), vegetables, fibre, and nutrient-dense foods
• •Protein target: Aim for 1.2–1.6g of protein per kilogram of body weight daily. This is crucial for preserving lean muscle mass during weight loss
• •Physical activity: Resistance training is particularly important during GLP-1-mediated weight loss to minimise muscle loss. Aim for 2–3 resistance sessions per week alongside regular aerobic activity
• •Behavioural changes: Use the appetite suppression as a window to establish healthier eating patterns. The medication makes it easier to change behaviours, but those behaviours need to become habits for long-term success

Long-term considerations:

• •Treatment duration: Current evidence and NICE guidance support treatment for up to 2 years on the NHS, with reassessment thereafter. Some patients may continue longer, particularly if cardiovascular risk reduction is a primary goal
• •Weight regain after stopping: The STEP 4 withdrawal study showed that approximately 60–70% of weight lost is regained within 12 months of stopping treatment. This is not a failure of willpower — it reflects the fact that obesity involves persistent biological changes in appetite regulation
• •Ongoing treatment vs. stopping: The decision to continue or stop Wegovy should be made collaboratively with your prescriber, weighing the benefits of continued weight maintenance against cost, side effects, and personal preference
• •Transitioning from NHS to private: If NHS funding ends (e.g., after the recommended 2-year treatment period), some patients choose to continue with private prescriptions. Discuss this possibility with your prescriber in advance

Monitoring recommendations:

• •Body composition: If possible, track body composition (lean mass and fat mass) rather than just weight. DEXA scans or bioimpedance measurements can help ensure muscle is being preserved
• •Blood work: Comprehensive metabolic panel, lipids, HbA1c, and liver function at baseline, 3 months, 6 months, and then every 6–12 months
• •Nutritional status: Monitor for micronutrient deficiencies (iron, B12, vitamin D, folate) which can develop with sustained reduced dietary intake
• •Mental health: Weight loss medications can sometimes affect mood, body image, or disordered eating patterns. Report any psychological changes to your prescriber

A final note on expectations:

Wegovy is the most effective licensed weight loss medication available in the UK, but it is not a miracle drug. Mean weight loss of 15–17% translates to meaningful health improvements — reduced cardiovascular risk, improved metabolic markers, better mobility, and enhanced quality of life. However, it works best as part of a comprehensive approach that includes dietary improvements, physical activity, and behavioural change.

This article is for educational purposes only and does not constitute medical advice. Consult a qualified healthcare professional before starting or adjusting any weight management medication.